 Oligopeptides
"Oligopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides composed of between two and twelve amino acids.
| Descriptor ID |
D009842
|
| MeSH Number(s) |
D12.644.456
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligopeptides".
Below are MeSH descriptors whose meaning is more specific than "Oligopeptides".
This graph shows the total number of publications written about "Oligopeptides" by people in this website by year, and whether "Oligopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 2 | 3 | 5 | | 1985 | 1 | 1 | 2 | | 1986 | 1 | 1 | 2 | | 1987 | 1 | 0 | 1 | | 1989 | 0 | 1 | 1 | | 1990 | 2 | 1 | 3 | | 1991 | 2 | 0 | 2 | | 1992 | 3 | 0 | 3 | | 1993 | 0 | 3 | 3 | | 1994 | 1 | 2 | 3 | | 1995 | 4 | 0 | 4 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 3 | 4 | | 1999 | 3 | 2 | 5 | | 2000 | 0 | 4 | 4 | | 2001 | 2 | 2 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 2 | 4 | | 2004 | 1 | 4 | 5 | | 2005 | 4 | 1 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 5 | 1 | 6 | | 2008 | 1 | 2 | 3 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 3 | 5 | | 2011 | 5 | 2 | 7 | | 2012 | 5 | 7 | 12 | | 2013 | 3 | 5 | 8 | | 2014 | 7 | 2 | 9 | | 2015 | 1 | 1 | 2 | | 2016 | 3 | 4 | 7 | | 2017 | 4 | 3 | 7 | | 2018 | 2 | 1 | 3 | | 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Oligopeptides" by people in Profiles.
-
Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019 09; 33(9):2127-2143.
-
Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431.
-
Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019 01 04; 9(1):3.
-
Gupta A, Xu J, Lee S, Tsai ST, Zhou B, Kurosawa K, Werner MS, Koide A, Ruthenburg AJ, Dou Y, Koide S. Facile target validation in an animal model with intracellularly expressed monobodies. Nat Chem Biol. 2018 09; 14(9):895-900.
-
D'Cruz AA, Kershaw NJ, Hayman TJ, Linossi EM, Chiang JJ, Wang MK, Dagley LF, Kolesnik TB, Zhang JG, Masters SL, Griffin MDW, Gack MU, Murphy JM, Nicola NA, Babon JJ, Nicholson SE. Identification of a second binding site on the TRIM25 B30.2 domain. Biochem J. 2018 01 23; 475(2):429-440.
-
Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 10; 36(8):728-734.
-
Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
-
Jakubowiak AJ, Houisse I, Májer I, Benedict Á, Campioni M, Panjabi S, Ailawadhi S. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 12; 10(12):1107-1119.
-
Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30; 8(22):35863-35876.
-
Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017 Dec; 22(10):585-591.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|